A detailed history of Two Sigma Investments, LP transactions in Allakos Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 59,089 shares of ALLK stock, worth $75,043. This represents 0.0% of its overall portfolio holdings.

Number of Shares
59,089
Holding current value
$75,043
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.54 - $0.92 $31,908 - $54,361
59,089 New
59,089 $38,000
Q1 2023

May 15, 2023

BUY
$4.3 - $8.27 $86,030 - $165,457
20,007 Added 66.25%
50,207 $223,000
Q4 2022

Feb 14, 2023

BUY
$5.66 - $8.42 $170,932 - $254,284
30,200 New
30,200 $254,000
Q2 2022

Aug 15, 2022

SELL
$2.6 - $6.14 $97,593 - $230,471
-37,536 Reduced 3.44%
1,052,332 $3.29 Million
Q1 2022

May 16, 2022

BUY
$5.08 - $9.81 $870,381 - $1.68 Million
171,335 Added 18.65%
1,089,868 $6.21 Million
Q4 2021

Feb 14, 2022

BUY
$8.55 - $111.89 $7.53 Million - $98.5 Million
880,348 Added 2305.48%
918,533 $8.99 Million
Q3 2021

Nov 15, 2021

SELL
$76.53 - $110.43 $13.8 Million - $19.9 Million
-180,236 Reduced 82.52%
38,185 $4.04 Million
Q2 2021

Aug 16, 2021

BUY
$85.37 - $114.1 $6.85 Million - $9.15 Million
80,205 Added 58.03%
218,421 $18.6 Million
Q1 2021

May 17, 2021

BUY
$109.73 - $153.66 $14.4 Million - $20.1 Million
130,797 Added 1763.0%
138,216 $15.9 Million
Q4 2020

Feb 16, 2021

SELL
$79.58 - $152.45 $935,065 - $1.79 Million
-11,750 Reduced 61.3%
7,419 $1.04 Million
Q3 2020

Nov 16, 2020

BUY
$66.43 - $90.99 $1.27 Million - $1.74 Million
19,169 New
19,169 $1.56 Million
Q2 2020

Aug 14, 2020

SELL
$44.04 - $80.69 $1.45 Million - $2.66 Million
-32,984 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$44.49 - $93.39 $1.47 Million - $3.08 Million
32,984 New
32,984 $1.47 Million

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $108M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.